ES2107464T3 - Compuestos agonistas del receptor h3 de la histamina para utilizacion terapeutica, composiciones farmaceuticas que actuan como agonistas de dicho receptor y procedimiento de preparacion. - Google Patents

Compuestos agonistas del receptor h3 de la histamina para utilizacion terapeutica, composiciones farmaceuticas que actuan como agonistas de dicho receptor y procedimiento de preparacion.

Info

Publication number
ES2107464T3
ES2107464T3 ES91910312T ES91910312T ES2107464T3 ES 2107464 T3 ES2107464 T3 ES 2107464T3 ES 91910312 T ES91910312 T ES 91910312T ES 91910312 T ES91910312 T ES 91910312T ES 2107464 T3 ES2107464 T3 ES 2107464T3
Authority
ES
Spain
Prior art keywords
receptor
pharmaceutical compositions
compounds
pct
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910312T
Other languages
English (en)
Inventor
Monique Garbarg
Jean-Michel Arrang
Walter Schunack
Ralph Lipp
Holger Stark
Jeanne-Marie Lecomte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet SC, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Bioprojet SC
Application granted granted Critical
Publication of ES2107464T3 publication Critical patent/ES2107464T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LOS COMPUESTOS PROCEDEN DE UNA AMINA R-NH SUB 2 QUE TIENE UNA FUERTE AFINIDAD PARA EL RECEPTOR H SUB 3 DE LA HISTAMINA Y CON FUNCION AMINA PRIMARIA CON LA QUE ESTA UNIDO UN GRUPO QUE DETERMINA UN ENLACE LENTAMENTE HIDROLIZABLE EN MEDIO NEUTRO. LAS COMPOSICIONES FARMACEUTICAS COMPRENDEN ESTOS COMPUESTOS Y UN VEHICULO O EXIPIENTE FARMACEUTICAMENTE ACEPTABLE. ESTOS COMPUESTOS SE UTILIZAN PARA LA REALIZACION DE UN MEDICAMENTO INHIBIDOR DE LA SINTESIS Y DE LA LIBERACION DE HISTAMINA, EN PARTICULAR CON EFECTOS SEDANTES, REGULADOR DEL SUEÑO, ANTICONVULSIVO, ANTIDEPRESIVO, ANTIALERGICO, ANTIINFLAMATORIO, ANTISECRETORIO O ANTIULCEROSO.
ES91910312T 1990-05-09 1991-05-10 Compuestos agonistas del receptor h3 de la histamina para utilizacion terapeutica, composiciones farmaceuticas que actuan como agonistas de dicho receptor y procedimiento de preparacion. Expired - Lifetime ES2107464T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9005776A FR2661909B1 (fr) 1990-05-09 1990-05-09 Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.

Publications (1)

Publication Number Publication Date
ES2107464T3 true ES2107464T3 (es) 1997-12-01

Family

ID=9396429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910312T Expired - Lifetime ES2107464T3 (es) 1990-05-09 1991-05-10 Compuestos agonistas del receptor h3 de la histamina para utilizacion terapeutica, composiciones farmaceuticas que actuan como agonistas de dicho receptor y procedimiento de preparacion.

Country Status (11)

Country Link
US (1) US5342960A (es)
EP (1) EP0482183B1 (es)
JP (1) JP3094384B2 (es)
AT (1) ATE156121T1 (es)
CA (1) CA2063550C (es)
DE (1) DE69127045T2 (es)
DK (1) DK0482183T3 (es)
ES (1) ES2107464T3 (es)
FR (1) FR2661909B1 (es)
GR (1) GR3024991T3 (es)
WO (1) WO1991017146A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662588B2 (en) * 1991-12-18 1995-09-07 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine H3 agonists/antagonists
US5633250A (en) * 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
EP0633882A1 (en) * 1992-04-01 1995-01-18 The University Of Toledo 4- 4'-piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof
US5639775A (en) * 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
JP2000189171A (ja) 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd 新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
AU3033100A (en) 1999-01-18 2000-08-01 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
CA2483701A1 (en) 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Constitutively active histamine h3 receptor mutants and uses thereof
EP1879567A1 (en) 2005-04-28 2008-01-23 Pfizer Limited Amino acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT71651B (en) * 1979-08-15 1982-01-21 Merck & Co Inc Process for preparing allysulfoxide enzyme inhibitors
FR2548183B1 (fr) * 1983-07-01 1985-10-31 Synthelabo Diphenylazomethines portant un radical imidazolyle, leur preparation et leur application en therapeutique
NL8501093A (nl) * 1985-04-12 1986-11-03 Stamicarbon Werkwijze voor het racemiseren van een optisch aktief n- benzylideenaminozuuramide.
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique

Also Published As

Publication number Publication date
FR2661909B1 (fr) 1997-08-14
US5342960A (en) 1994-08-30
ATE156121T1 (de) 1997-08-15
JPH06501241A (ja) 1994-02-10
EP0482183A1 (fr) 1992-04-29
GR3024991T3 (en) 1998-01-30
WO1991017146A1 (fr) 1991-11-14
DE69127045T2 (de) 1998-03-05
DK0482183T3 (da) 1998-03-09
DE69127045D1 (de) 1997-09-04
FR2661909A1 (fr) 1991-11-15
CA2063550A1 (en) 1991-11-10
JP3094384B2 (ja) 2000-10-03
EP0482183B1 (fr) 1997-07-30
CA2063550C (en) 2002-02-26

Similar Documents

Publication Publication Date Title
ES2107464T3 (es) Compuestos agonistas del receptor h3 de la histamina para utilizacion terapeutica, composiciones farmaceuticas que actuan como agonistas de dicho receptor y procedimiento de preparacion.
MX9300261A (es) Derivados de 1,5-benzodiacepina, proceso para su preparacion y composicion farmaceutica que los contiene.
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
EP0916346A3 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ES2137991T3 (es) Eniantinas y derivados de eniantina para la lucha contra los endoparasitos.
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
NZ297879A (en) Ondansetron and polyhydric alcohol (a sweetener) in a liquid acidic oral composition form
ES2119160T3 (es) Derivados de tiazolidina, su preparacion y los medicamentos que les contienen.
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
ATE171066T1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
ES2172600T3 (es) Composicion farmaceutica que comprende lamotrigina.
ECSP941120A (es) Derivados de 1,5 benzodiazepina
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
AR003107A1 (es) Derivados de vitamina d para uso dermatologico, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
BR9504230A (pt) Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto
SE9103022D0 (sv) Nya 5h-bensodiazepinderivat, farmaceutiska kompositioner innehaallande desamma samt foerfarande foer framstaellning av dessa
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
MY130757A (en) Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
FI950209A0 (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
CO4480740A1 (es) Polimorfos del profarmaco de 6-n-(l-ala-l-ala)-trovafloxaci- na
ES2191106T3 (es) Uso de ondansetron en la fabricacion de un medicamento para el tratamiento del temblor.
MY106292A (en) (alpha)-adrenergic receptor antagonists.
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482183

Country of ref document: ES